论文部分内容阅读
目的探讨替米沙坦联合前列地尔治疗糖尿病肾病的临床效果。方法选择2007年4月至2011年4月期间在我院接受治疗的120例糖尿病肾病患者作为研究对象,随机分为三组,每组30例患者。前列地尔组给予前列地尔;替米沙坦组给予替米沙坦;联合治疗组给予替米沙坦与前列地尔联合治疗。观察治疗前后三组患者的血压、微量白蛋白水平的情况。结果三组患者治疗后微量白蛋白均下降(P<0.01),血糖水平控制也较好。联合治疗组的疗效优于前列地尔组和替米沙坦组,结果具有统计学意义。结论替米沙坦和前列地尔联合应用,可以更好的延缓病情发展,保护肾脏,作为一种临床上有效的治疗糖尿病肾病的方法。
Objective To investigate the clinical effect of telmisartan and alprostadil in the treatment of diabetic nephropathy. Methods A total of 120 patients with diabetic nephropathy treated in our hospital from April 2007 to April 2011 were selected and randomly divided into three groups of 30 patients. Alprostadil was administered to the alprostadil group, telmisartan was given to the telmisartan group, telmisartan and alprostadil were given to the combined treatment group. Observed before and after treatment in three groups of patients with blood pressure, microalbumin levels. Results After treatment, the levels of microalbumin decreased (P <0.01) and the control of blood glucose level was also better. The efficacy of the combination therapy group is superior to the alprostadil group and telmisartan group, the results were statistically significant. Conclusion The combination of telmisartan and alprostadil can delay the progression of the disease and protect the kidneys as a clinically effective method for the treatment of diabetic nephropathy.